PNH is a rare, complex, and fatal acquired blood disorder in which a dysregulation of the complement system destroys red blood cells, leading to hemolysis. The initial symptoms of most patients are related to hemolysis or anemia, such as cramping abdominal pain, headache, back pain, fatigue, fever, etc., and hemolysis is more likely to occur during nighttime sleep. About 1/4 of the patients have hemoglobinuria as the first symptom, and the appearance of the urine is black tea or black, and it will return to normal in a few days; 1/3 of the patients may have abnormal white blood cells or platelets and produce related symptoms, such as infection, skin Purple spot etc.
At present, in many countries and regions, the treatment of PNH is relatively limited, mainly anti-C5 monoclonal antibody, but because of its high treatment cost, many patients cannot afford it. In view of this, Beihai Kangcheng developed CAN106 under the empowerment of WuXi Biologics, and has the exclusive global development and commercialization rights of CAN106, and is conducting phase Ib/II trials for the treatment of PNH in China. According to past data, CAN106 can reduce the level of free C5 in healthy volunteers to over 99%. It has good safety, high activity and long half-life, which supports the possibility of prolonged dosing intervals for PNH patients. PNH patients offer meaningful treatment options.
Beihai Kangcheng scientific research team
